Skip to main navigation Skip to search Skip to main content

Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7/8 adjuvant for robust protection against heterologous pandemic and endemic viruses

  • Yeon Jeong Yoo
  • , Suhyeon Kim
  • , Asha Wickramasinghe
  • , Jaemoo Kim
  • , Ju A. Song
  • , Young Il Kim
  • , Juryeon Gil
  • , Young Woock Noh
  • , Min Ho Lee
  • , Sang Seok Oh
  • , Myeong Mi Lee
  • , Yebin Seong
  • , Jong Soo Lee
  • , Young Ki Choi
  • , Yong Taik Lim
  • Sungkyunkwan University
  • Chungnam National University
  • Institute for Basic Science
  • Chungbuk National University
  • Osong Medical Innovation Foundation

Research output: Contribution to journal › Article › peer-review

Abstract

The demand for safe vaccines that ensure long-term and broad protection against multiple viral variants has dramatically increased after the emergence of catastrophic infectious diseases such as COVID-19. To ensure long-term and broad protection against heterologous virus variants, antigen-specific polyfunctional T cells should be orchestrated with the activation of follicular helper T (TFH) cells and germinal center (GC) B cells. Herein, we suggest a novel engineered nanoadjuvant (SE(Trojan-TLR7/8a)) that enhances the migration of nonexhausted antigen-presenting cells (APCs) into lymph nodes and elicits the activation of TFH cells, the generation of GC B cells, and polyfunctional T cells via multiscale dynamic immunomodulation through squalene nanoemulsion (SE)-mediated macroscopic control of vaccine delivery and Trojan-TLR7/8a-enabled dynamic and sustained activation of APCs at the cellular level. SE(Trojan-TLR7/8a) can be lyophilized, reduce systemic toxicity, and outperform current commercial vaccine adjuvants (Alum or AS03) and mRNA vaccines. SE(Trojan-TLR7/8a) ensures cross-protection against diverse influenza and SARS-CoV-2 variants, providing 100% protection while maintaining a healthy state. SE(Trojan-TLR7/8a) also sustains a potent T-cell response in an aged ferret model of SFTSV infection. SE(Trojan-TLR7/8a) suggested herein provides a novel vaccine design principle for dynamic modulation at the multiscale level and demonstrates long-term and broad protective immunity against emerging pandemic and endemic infectious viruses.

Original languageEnglish
Pages (from-to)1045-1060
Number of pages16
JournalCellular and Molecular Immunology
Volume22
Issue number9
DOIs
StatePublished - Sep 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Dynamic immunomodulation
  • Heterologous viruses
  • Nanoemulsion
  • TLR7/8 agonist
  • Vaccine adjuvant

Fingerprint

Dive into the research topics of 'Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7/8 adjuvant for robust protection against heterologous pandemic and endemic viruses'. Together they form a unique fingerprint.

Cite this